ClinicalTrials.gg
RecruitingNCT04743180LUMIFOLLOWUpdated Feb 11, 2021

European All-comers' Multicentric Prospective REGISTRY on LUMINOR© Drug Eluting Balloon in the Superficial Femoral Artery and Popliteal Artery With 5 Years Follow-up.

An observational study in Angioplasty, Peripheral Arterial Disease and Drug-eluting Balloon, sponsored by iVascular S.L.U.. Recruiting at 15 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-11.

Sponsored by iVascular S.L.U. · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2022, 4 years 5 months ago, but the record still lists the study as recruiting.
  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 120 studies in Peripheral Arterial Disease with a site in France — 21 open to participants now, 27 under way, 4 of them phase 3. Peripheral Arterial Disease · France.

Planned enrollment
18th of 54
500 · median 298
Started
2021
with 10 others
Observational
54 of 120
8 open now
Primary completion
2022-06
later than 0 of 26 live
Registered
84th of 120
by date

Among the 120 studies in Peripheral Arterial Disease with a site in France, this one is the 18th largest by planned enrollment of the 54 observational ones that give a count, is one of 11 that started in 2021, is one of 54 observational ones, reaches primary completion later than 0 of the 26 other live ones, and was the 84th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

21 of the 120 studies in Peripheral Arterial Disease with a site in France are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Peripheral Arterial Disease with a site in France, or all of them as a file.
02

Study summary

The objective of this all-comers registry is to explore the safety, efficacy, and cost-efficiency of the LUMINOR© DEB in de-novo and restenotic-FP lesions. For de-novo and restenotic lesions, especially for calcified and/or long lesions/occlusions, the use of debulking devices to improve recalibration and drug penetration will be evaluated in a specific sub-group.

03

Conditions studied

  • Angioplasty
  • Peripheral Arterial Disease
  • Drug-eluting Balloon
  • Femoral Artery
  • Paclitaxel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with peripheral artery disease due to occlusive lesions, stenosis of ingraguinal arteries and restenosis after previous angioplasty with/without stent in that sector.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years of age
  • Rutherford Clinical Category 2-5
  • The subject is legally competent, has been informed of the nature, the scope, and the relevance of the study, voluntarily agrees to participation, is willing to provide 5-year and has duly signed the informed consent form (ICF)
  • Significant (≥ 70%) stenosis or occlusion of a native femoropopliteal artery
  • TASC II Class A to D Lesions
  • de novo lesion(s), non-stented or stented restenotic lesion(s)
  • Proximal margin of target lesion(s) starts at the ostium of the superficial femoral artery, just below the common femoral bifurcation
  • Distal margin of target lesion(s) terminates at bifurcation of popliteal artery AND ≥1 cm above the origin of the TP trunk (P3)
  • A patent inflow artery free from significant lesion (≥ 50% stenosis) as confirmed by angiography (treatment of target lesion acceptable after successful treatment of iliac or common femoral inflow artery lesions); Successful inflow artery treatment is defined as attainment of residual diameter stenosis ≤ 30% without death or major vascular complication
  • Successful wire crossing and pre-dilatation (1min min, with under sizing of 1mm compared to ref diameter) of the target lesion; Use of crossing devices allowed if necessary. Use of laser or atherectomy is allowed if necessary, during the index procedure. Bailout stenting is allowed if necessary, after DEB use
  • At least one patent native outflow artery to the ankle, free from significant (≥ 50%) stenosis as confirmed by angiography (treatment of outflow disease is NOT permitted during the index procedure)

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant, lactating, or planning on becoming pregnant or men intending to father children
  • Patient is to use Luminor Drug Eluting Balloon per the current Instructions For Use (IFU)
  • of \< 1year
  • Patient is currently participating in an drug or other device study or previously enrolled in this study
  • Inability to take required study medications or allergy to contrast that cannot be adequately managed with pre- and post-procedure medication
  • Sudden symptom onset, acute vessel occlusion, or acute or sub-acute angiographically visible thrombus in target vessel
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
60 Months
Patient registry
Yes

Groups and cohorts

  • LUMINOR© drug eluting balloon

    Device: LUMINOR© Paclitaxel eluting balloon

Interventions

  • DeviceLUMINOR© Paclitaxel eluting balloon

    Patients will be treated with the Luminor paclitaxel eluting balloon

06

What researchers measure

Primary outcomes

  1. Primary Endpoint Efficacy measured by presence of primary patency of the target lesion based on ultrasound images

    Primary Patency is defined as Freedom from Clinically-Driven Target Lesion Revascularization and from Binary Restenosis.

    Time frame: 12 Months

  2. Overall Medical Safety

    Combination assessment of freedom from all-cause peri-procedural (≤30 day) death and freedom at 3 years from the following: index limb amputation (above or below the ankle), and all-cause mortality (with a detailed analysis of cardiovascular (CV) and non-CV deaths). Success is defined as freedom from all specified events; failure is defined as one or more specified events occurrences.

    Time frame: 36 Months

Secondary outcomes

  1. Secondary Endpoint Medical Safety: Major vascular complications

    Major vascular complications will be counted: * Haematoma at access site \>5 cm * False aneurysm * AV fistula * Retroperitoneal bleeding * Peripheral ischemia/nerve injury * Any transfusion required will be reported as a vascular complication unless clinical indication clearly other than catheterization complication * Vascular surgical repair

    Time frame: ≤30 days after index procedure

  2. Secondary Endpoint Medical Safety: Composite Safety

    Combination assessment of freedom from all-cause death and freedom from the following: index limb amputation (above or below the ankle = major or minor amputation) and index limb re-intervention. Success is freedom from all specified events; failure is occurrence of one or more specified events.

    Time frame: 1, 6, 12, 36, 48, 60 months after index procedure

  3. Secondary Endpoint Medical Safety: All-cause death

    Death by any cause will be counted and stratified between CV and non-CV deaths. Cause of death will be analyzed to search for any specific increase of a death's subtype.

    Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure

  4. Secondary Endpoint Medical Safety: Major amputation at target limb

    Amputations above the ankle of the target leg will be counted. Optional histologic examination of fixed muscle segments in 10% neutral-buffered formalin could be performed in the Inserm unit 1034, Pessac, France to search for paclitaxel microparticle deposits, fibrinoid necrosis artery wall injury, inflammation, thrombus, hemorrhage, and fibrosis. Adjacent nonfixed samples of similar distal tissues, flash-frozen in liquid nitrogen, and retained at -80°C will be used for bioanalysis of paclitaxel levels by modified liquid chromatography/tandem mass spectroscopy.

    Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure

  5. Secondary Endpoint Medical Safety: Minor amputation at target limb

    Amputations below the ankle of the target leg will be counted.

    Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure

  6. Secondary Endpoint Medical Safety: Target Vessel Revascularization (TVR)

    Repeat intervention at the target vessel will be counted.

    Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure

  7. Secondary Endpoint Medical Safety: Target Limb Reintervention

    Repeat intervention at the target leg will be counted.

    Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure

  8. Secondary Endpoint Efficacy: Acute Device Success

    Device success is defined as, a per device basis, the achievement of successful delivery and deployment of the study device(s) as intended at the intended target lesion, without balloon rupture or inflation/deflation abnormalities and a successful withdrawal of the study system. If a device is inserted into the subject but not used due to user error (e.g. inappropriate balloon length or transit time too long), this device will not be included in the device success assessment.

    Time frame: During index procedure

  9. Secondary Endpoint Efficacy: Technical Success

    Technical Success of the balloon procedure is defined as successful access and deployment of the device and visual estimate of ≤ 30% diameter residual stenosis during the index procedure.

    Time frame: During index procedure

  10. Secondary Endpoint Efficacy: Procedural Success

    Attainment of ≤ 30% residual stenosis in the treatment area without major adverse events (defined as occurrence of death, major amputation of the target limb, target vessel or distal revascularization) during the index procedure and through the hospital stay.

    Time frame: Up to 30 days

  11. Secondary Endpoint Efficacy: Primary Patency

    Primary Patency is defined as Freedom from Clinically-Driven Target Lesion Revascularization and from Binary Restenosis. Binary restenosis is adjudicated by the validated center based on threshold Doppler PSVR ≥ 2.5 (together with waveform analysis \& color mosaic appearance) or based on angiographic ≥ 50% diameter stenosis (if angiography is performed although not required per protocol).

    Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure

  12. Secondary Endpoint Efficacy: Secondary Patency

    Secondary Patency of the target lesion is defined as the absence of binary restenosis as adjudicated by the validated center, independent of whether or not patency is re-established via an endovascular procedure.

    Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure

  13. Secondary Endpoint Efficacy: Clinically-driven Target Lesion Revascularization (TLR)

    Revascularization of the target lesion with evidence of diameter stenosis \>50% determined by duplex ultrasound or angiography and new distal ischemic signs (worsening ABI or worsening Rutherford Category associated with the target limb or due to clinical symptoms).

    Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure

  14. Secondary Endpoint Efficacy: Target Lesion Revascularization (TLR)

    A repeat revascularization procedure (percutaneous or surgical) of the original target lesion site.

    Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure

  15. Secondary Endpoint Efficacy: Change of Rutherford classification from baseline

    Patients are enrolled with a Rutherford grade of 2-5 for their target leg. The Rutherford scale is an indicator for the severity of Peripheral Vascular Disease: 0 = no symptoms, 6 = functional foot is no longer salvageable (leading to foot amputation).

    Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure

  16. Secondary Endpoint Efficacy: Change of resting Ankle Brachial Index (ABI) from baseline

    The ABI values will be recorded and compared to the baseline values. The ABI is the ratio of the blood pressure at the ankle to the blood pressure in the upper arm. A ratio of 0.9-1.3 is in the normal range. Lower ratios indicate bad blood perfusion of the leg.

    Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure

  17. Secondary Endpoint Efficacy: Change in Walking Impairment Questionnaire from baseline

    The Walking Impairment Questionnaire values will be recorded and compared to the baseline values.

    Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure

  18. Secondary Endpoint Efficacy: Change in quality of life from baseline, as measured by EQ-5D

    The EQ-5D Questionnaire values will be recorded and compared to the baseline values.

    Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure

  19. Secondary Endpoint Cost-Effectiveness (optional): factoring procedure and hospital admission costs

    Time frame: 1, 6, 12, 24, 36, 48, 60 months after index procedure

07

Study locations

15 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Jun 2022, 17 months after the start.

Of 58 industry-sponsored observational studies under Peripheral Arterial Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 17 months is below that.

Counting every sponsor, half of 196 studies reached it within 36 months; a quarter within 22 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2021
First posted
Feb 8, 2021
StartActual
Jan 18, 2021
Primary completionEst.
Jun 2022
CompletionEst.
Jun 30, 2026
Last update
Feb 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04743180
Lead sponsor
iVascular S.L.U.
Responsible party
Sponsor
First posted
Feb 8, 2021
Start date
Jan 18, 2021
Primary completion
Jun 2022 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Feb 11, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion